Physician profile
Amjad Mreyoud
NPI 1518107051
$5,440.11
in general payments reported to CMS, 2019-2025
33 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $70.83 · 2021: $169 · 2022: $562 · 2023: $1,067 · 2024: $1,743 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,887.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,678.57 | 2019-2025 | |
| Janssen Biotech, INC. | $575.21 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $532.15 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $465.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $310.20 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $174.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $141.42 | 2020-2025 | |
| Enterra Medical, INC. | $136.33 | 2024 | |
| Medtronic, INC. | $125.84 | 2024 | Nexpowder |
| Covidien LP | $115.14 | 2019 | |
| Ironwood Pharmaceuticals, INC | $108.34 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $108.00 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $105.92 | 2023-2025 | Exalt Model D, General - Hemostasis |
| Intercept Pharmaceuticals, INC. | $105.61 | 2019-2024 | Ocaliva |
| Cook Medical LLC | $87.99 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $76.77 | 2019-2023 | Rebyota |
| Genzyme Corporation | $69.82 | 2023-2024 | |
| Veloxis Pharmaceuticals, INC. | $61.60 | 2022 | |
| Lilly USA, LLC | $56.55 | 2025 | Omvoh |
| Ucb, INC. | $45.46 | 2019-2020 | |
| Qol Medical, LLC | $43.99 | 2019-2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $42.92 | 2019 | |
| Allergan, INC. | $35.02 | 2019 | |
| Ardelyx, INC. | $34.93 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $29.06 | 2019 | |
| Amgen INC. | $26.43 | 2023 | Avsola, Amjevita |
| Dova Pharmaceuticals | $26.12 | 2019 | |
| Heron Therapeutics, INC. | $24.47 | 2024 | Zynrelef |
| Janssen Pharmaceuticals, INC | $23.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.94 | 2022 | |
| Aimmune Therapeutics, INC. | $20.21 | 2024 | |
| Celltrion USA INC. | $19.82 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Mreyoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.